RJA
NMTC icon

Raymond James & Associates’s NeuroOne Medical Technologies NMTC Stock Holding History

Raymond James & Associates’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,900
Closed -$13.9K – 4068
2024
Q2 		$13.9K Buy
+2,900
New +$18.2K ﹤0.01% 3917

Other funds holding NMTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Raymond James & Associates's NMTC Position: Q3 2024 in Review

Raymond James & Associates sold out of NeuroOne Medical Technologies (NMTC) in Q3 2024, closing a stake of 2,900 shares — an estimated $13.9K sold.

Raymond James & Associates first reported a position in NMTC in Q2 2024 and held it in 1 quarter. The position peaked at $13.9K in Q2 2024. 21 funds tracked by Wall St. Rank hold NMTC as of Q3 2024.

  • Raymond James & Associates reported no remaining NeuroOne Medical Technologies position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 2,900 NeuroOne Medical Technologies shares in Q3 2024, an estimated $13.9K.
  • Raymond James & Associates first reported a position in NeuroOne Medical Technologies in Q2 2024 and held it in 1 quarter.
  • Raymond James & Associates's NeuroOne Medical Technologies position peaked at $13.9K in Q2 2024.
  • 21 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.